Annovis Bio Inc. (NYSE: ANVS)

The QualityStocks Daily Newsletter would like to spotlight Annovis Bio Inc. (NYSE: ANVS).

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's disease ("AD") and Parkinson's disease ("PD"), has filed three new patents. According to the announcement, the patents cover combination therapies involving its lead compound, buntanetap, combined with Trulicity(R)(dulaglutide) and Viagra(R)(sildenafil), as well as a combination of all three. The company noted buntanetap inhibits the production of neurotoxic proteins and has been shown to improve cognition in early AD patients and halt cognitive decline in PD patients.

"Our early data suggests a strong synergistic effect from combining these drugs, resulting in significant cognitive enhancement," said Annovis Bio founder, president and CEO Maria Maccecchini, PhD, in the press release. "The combination of buntanetap with Trulicity and Viagra not only has the potential to restore cognition to healthy levels, but also to improve it beyond normal, offering new hope in the fight against dementia. Since buntanetap has completed phase 3 studies as a standalone treatment, and both Trulicity and Viagra are FDA-approved, these combinations are well-positioned for phase 3 human trials."

To view the full press release, visit https://ibn.fm/mj0ug

Annovis Bio Inc. Overview

Annovis Bio Inc. (NYSE: ANVS) is a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as AD and PD. Annovis Bio stands out by developing a drug that targets multiple neurotoxic proteins simultaneously, aiming to restore axonal and synaptic activity. This innovative approach addresses both the cognitive decline in AD and the motor dysfunction in PD, making Annovis a unique player in the neurodegeneration space.

Lead Drug Candidate: Buntanetap

Buntanetap (formerly known as Posiphen) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This multifaceted inhibition improves synaptic transmission and axonal transport, reduces neuroinflammation, and protects nerve cells from dying. Unlike monoclonal antibody therapies, buntanetap is an orally available small molecule capable of inhibiting multiple neurotoxic proteins at once, positioning it as a comprehensive solution for neurodegenerative diseases.

In a recent Phase II/III Alzheimer’s study, buntanetap demonstrated statistically significant efficacy. Patients with early AD showed a significantly higher rate of improvement in ADAS-Cog 11 scores across all treatment doses compared to placebo, with a 3.3 point improvement compared to 0.3 for placebo (p < 0.01). Plasma Tau protein levels also reduced, consistent with previous Phase II biomarker data, further validating buntanetap’s mechanism of action.

Similarly, in the recently completed Phase III study of buntanetap in patients with early PD, buntanetap significantly improved disease-related daily non-motor and motor functions in Parkinson’s patients who had a diagnosis over 3 years as well as improved cognition in all PD patients. It further underscores buntanetap’s potential as a transformative therapy.

Market Opportunity

The aging population presents a significant market opportunity, with nearly 7 million Americans currently suffering from Alzheimer’s Disease (AD), a figure projected to rise to almost 13 million by 2050​ (Alzheimer’s Association)​​ (Republican Policy Committee)​. Additionally, approximately 1.2 million people in the U.S. have Parkinson’s Disease​ (SingleCare)​.

The economic burden of Alzheimer’s is immense, with care costs expected to reach $360 billion in 2024 and escalate to nearly $1 trillion annually by 2050​​. The need for effective, comprehensive treatments like Buntanetap is more critical than ever.

Company Highlights

• Innovative Therapeutic Approach: Annovis Bio uniquely targets multiple neurotoxic proteins, aiming to restore nerve cell health and improve cognitive and motor function in AD and PD patients.
• Robust Clinical Data: Phase II/III studies show significant improvements in cognitive function and biomarker levels in early AD patients.
• Groundbreaking Clinical Insights: Recent Phase III data in Parkinson’s Disease patients demonstrates significant improvements in motor and cognitive functions.
• Upcoming Phase III Trials: Plans are underway for an 18-month Phase III trial focusing on biomarker-positive early AD patients, designed to further validate buntanetap’s disease-modifying potential.
• Capital Efficiency: Annovis Bio is capital-efficient, with zero debt and multiple global patents extending into the 2040s.

Management Team

• Maria L. Maccecchini, Ph.D. – Founder, President, CEO, and Executive Board Member, founded Annovis Bio in May 2008 with the mission to develop better therapeutics for Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. She has previously been a partner and director at two angel groups, Robin Hood Ventures and MidAtlantic Angel Group, and founded Symphony Pharmaceuticals/Annovis, which was sold to Transgenomic in 2001. Her extensive experience includes roles such as General Manager at Bachem Bioscience and Head of Molecular Biology at Mallinckrodt. Dr. Maccecchini holds a Ph.D. in biochemistry from the Biocenter of Basel, with postdoctoral work at Caltech and the Roche Institute of Immunology.
• Cheng Fang, Ph.D. – Senior VP of Research and Development, is an accomplished neuroscientist with two decades of experience in neurodegenerative diseases. She has a successful track record of scientific publications and contributions, coupled with extensive pre-clinical and clinical development experience. Dr. Fang has been instrumental in advancing the understanding of neurodegenerative disease mechanisms and developing therapeutic strategies.
• Michael Christie, Ph.D. – VP of Process Chemistry, has over 40 years of experience in the pharmaceutical industry, focusing on process chemistry R&D, pilot plant production, and GMP operations. He has held senior management positions at companies such as SmithKline, Rhodia, Teva, and Cephalon, and founded a contract process R&D service company, which was later acquired by ChiRex. Dr. Christie is co-author or co-inventor on several publications and patents. He earned his BS in chemistry from the University of Michigan and his doctorate from MIT.
• Melissa Gaines – Senior VP of Clinical Operations, is an accomplished clinical research professional with over 20 years of experience across academia, contract research organizations, and pharmaceutical companies. She has proven abilities in monitoring and managing Phase I to IV clinical trials, specializing in CNS disorders and extending to a broad range of therapeutic indications. Her CNS experience spans from small Phase I and II studies to large global Phase III trials in Alzheimer’s disease, Parkinson’s disease, sleep disorders, and various psychiatric diseases in both adult and pediatric populations. In her current role, she oversees and supports all clinical project activities, driving operational success and ensuring high-quality clinical outcomes.

Annovis Bio Inc. (NYSE: ANVS), closed Monday's trading session at $8.06, off by 0.4938272%, on 108,317 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $4.53/$22.49.

Recent News

• Annovis Bio Inc. (NYSE: ANVS) - Addressing Vision Problems Could Lower Risk of Dementia, Study Finds
• Annovis Bio Inc. (NYSE: ANVS) Presented Recent Achievements and Strategic Direction at H.C. Wainwright Investment Conference
• BioMedNewsBreaks - Annovis Bio Inc. (NYSE: ANVS) Stands Distinct from Industry Players with Buntanetap

Clene Inc. (NASDAQ: CLNN)

The QualityStocks Daily Newsletter would like to spotlight Clene Inc. (NASDAQ: CLNN).

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, has entered into a securities purchase agreement. The company entered the agreement, which calls for the issue and sale of 742,626 shares of common stock (or prefunded warrants in lieu thereof) with a healthcare-focused institutional investor. The company also noted it had entered into additional agreement and placements with current investors as well as directors and officers of Clene. Gross proceeds from the transactions will total an estimated $7.3 million, before standard deductions and fees. Canaccord Genuity is acting as sole placement agent for the offerings, which are expected to close on or about Oct. 1, 2024.

To view the full press release, visit https://ibn.fm/xmPfT

Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Its lead drug candidate is CNM-Au8®, an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.

CNM-Au8

CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

Clene Inc. (NASDAQ: CLNN), closed Monday's trading session at $4.59, off by 4.7718%, on 96,731 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $3.8181/$13.20.

Recent News

• Clene Inc. (NASDAQ: CLNN) - InvestorNewsBreaks - Clene Inc. (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private Placements Totaling $7.3M
• Clene Inc. (NASDAQ: CLNN) to Discuss Lead Candidate CNM-Au8(R) Biomarker, Clinical Data for ALS with Food and Drug Administration Leadership
• InvestorNewsBreaks - Clene Inc. (NASDAQ: CLNN) Announces Upcoming In-Person FDA Meeting to Discuss CNM-Au8

D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

The strategic partnership between D-Wave and Staque aims to accelerate the commercial adoption of annealing quantum computing solutions in the region.

The two companies will leverage D-Wave's quantum computers and hybrid solvers to help customers develop and deploy quantum and hybrid quantum applications to address enterprise optimization and AI problems.

The partnership was revealed at the first-ever Qubits UAE event in Dubai, which was organized jointly by D-Wave, Staque, and Staque's regional partner, SquareOne.

D-Wave Quantum (NYSE: QBTS) ("D-Wave"), a leader in quantum computing systems, software and services, and the first commercial provider of quantum computers, announced a new strategic partnership with Staque, a leading consulting and development practice focused on AI, blockchain and quantum computing, designed to step up the commercial adoption of annealing quantum computing across the Middle East (https://ibn.fm/TNAND).

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer

 

With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service

 

D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

• Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
• Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
• Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Monday's trading session at $0.9829, off by 4.5728%, on 2,697,918 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.57/$2.44.

Recent News

• D-Wave Quantum Inc. (NYSE: QBTS) - A First in the Industry: Quantum Computer Fixes Own Errors
• InvestorNewsBreaks - D-Wave Quantum Inc. (NYSE: QBTS) Announces Partnership with Staque to Accelerate Commercial Adoption of Quantum in the Middle East
• D-Wave Quantum Inc. (NYSE: QBTS) Joins Chicago Quantum Exchange to Help Advance Quantum Science and Commercialization

Trillion Energy International Inc. (CSE: TCF) (OTCQB: TRLEF)

The QualityStocks Daily Newsletter would like to spotlight Trillion Energy International Inc. (CSE: TCF) (OTCQB: TRLEF).

Current challenges, including geopolitical tensions, are driving European nations to boost local production of natural gas.

Producing natural gas in Europe and Türkiye involves several challenges.

Amid these challenges, Trillion Energy International is stepping up to enhance natural gas production capabilities in the region.

Natural-gas production in Europe and Türkiye plays a pivotal role in the region's energy landscape, impacting economic stability and energy security. As European countries seek to transition away from fossil fuels while balancing energy demands, the natural-gas sector remains crucial. Trillion Energy International (CSE: TCF) (OTCQB: TRLEF), a Canadian oil-and-gas exploration and production company, is dedicated to becoming a key player in this space.

Trillion Energy International Inc. (CSE: TCF) (OTCQB: TRLEF), along with its consolidated subsidiaries, is a Canadian oil and gas exploration and production company with operations primarily focused in the Republic of Türkiye.

Headquartered in Canada, the company owns 49% of the SASB natural gas field, which is producing critical domestic supply of natural gas during Europe’s ongoing energy shortages. It also holds a 19.6% (except three wells with 9.8%) ownership interest in the Cendere Oil Field and has a farm-in agreement to earn 50% interest in three oil exploration blocks in southeast Türkiye called Cudi-Gabar.

Trillion Energy utilizes state-of-the-art technology and ingenious practices to produce and distribute oil and natural gas while still maintaining a commitment to sustainable and responsible operations. Whether through the development of new projects or optimizing existing assets, the company continues to seek new and innovative ways to drive growth and value for its stakeholders.

Headquartered in Vancouver, British Columbia, Trillion Energy is led by seasoned professionals who collectively boast over a century of energy exploration and development experience.

Projects

SASB Gas Field

The SASB Gas Field is producing and delivering critical domestic supplies of natural gas as energy shortages grip Europe due to Russia’s invasion of Ukraine.

Located in the southwestern Black Sea, the SASB gas field consists of numerous conventional natural gas pools located in shallow water. The fields have produced over 43 billion cubic feet (BCF) since initial development in 2007 and continue to provide much needed energy to Türkiye and the EU. Total infrastructure to date, including production platforms, pipelines, initial wells and gas processing plant, cost in excess of $600 million.

Trillion Energy is redeveloping the field with a strategic planned program of approximately 17 wells which commenced in 2022. Phase B of the program, targeted for 2024/25, consists of the re-entry of five legacy wells to drill sidetrack development wells and one exploration stratigraphic well.

Cendere Oil Field

Trillion Energy’s Cendere oil field is a long-term, low decline, stable oil production field located in Türkiye. The company has a 19.6% interest in the field, except for three wells in which its interest is 9.8%.

Cash flow after operating costs from the field is $120,000 to $140,000 per month, with average current production netting the company 110-120 barrels of oil per day. Estimated remaining Cendere oil reserves total 1.5 million barrels (0.277 million barrels net Trillion Energy).

The gross value of Trillion Energy’s interest is estimated at $13.85 million (NPV10).

Cudi-Gabar

Trillion Energy’s 10-well oil exploration drilling program is occurring on three prospective oil blocks located in the prolific Cudi-Gabar oil province in southeast Türkiye. The total area of the three blocks is 374,325 acres.

Trillion Energy’s potential 50% working and revenue interest in the blocks is earned by paying 100% of the work program costs. The company will operate the exploration program.
During 2023/24, Trillion Energy will shoot 351 kilometers of 2D seismic (150 km already shot on the eastern block) and drill four wells. The remaining six wells will be paid 50% by Trillion and 50% by the company’s partner. The oil blocks are surrounded by more than 10 major oil discoveries, half of which are recent.

Market Opportunity

A January 2024 report by Emergen Research, a market research and consulting company, estimated the global natural gas market at $310.5 trillion in 2022 and projected the market will be worth $443.8 trillion by 2032, achieving a CAGR of 3.7% during the forecast period. Increasing global economic activity and rising electricity consumption are key factors driving revenue growth of the market, according to the report.

Trillion Energy reports strong demand for natural gas in Türkiye, which is the seventh-largest natural gas consuming country in the world. Türkiye currently imports 98% of the natural gas it consumes, with about 60% of those imports coming from Iran and Russia.

Management Team

Dr. Arthur Halleran is CEO and Director of Trillion Energy. He has a Ph.D. in Geology from the University of Calgary and 44 years of petroleum exploration and development experience. His international experience includes work in Canada, Colombia, Egypt, India, Guinea, Sierra Leone, Sudan, Suriname, Chile, Brazil, Bulgaria, Türkiye, Pakistan, Peru, Tunisia, Trinidad Tobago, Argentina, Ecuador and Guyana. Dr. Halleran has worked for Petro-Canada, Chevron, Rally Energy and United Hydrocarbon International Corp. In 2007, he founded Canacol Energy Ltd., now the largest natural gas producer in Colombia.

Al Thorsen is COO of Trillion Energy. He is responsible for production operations of the SASB gas field, as well as future drilling activities in Türkiye and abroad. Highlights of his career include Valeura Energy Inc. as operations manager in Türkiye; Journey Energy, leading a production team; Rio Alto Exploration as country manager and production manager; Zargon Oil and Gas as VP of Operations; Orleans Energy as VP of Operations; and Central Petroleum as COO. He holds a Bachelor of Science in Petroleum Engineering from Montana College of Mineral Science & Technology.

Trillion Energy International Inc. (OTCQB: TRLEF), closed Monday's trading session at $0.0857, off by 7.9484%, on 316,421 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0682/$0.8213.

Recent News

• Trillion Energy International Inc. (CSE: TCF) (OTCQB: TRLEF) - Trillion Energy International Inc. (CSE: TCF) (OTCQB: TRLEF) Focused on Optimizing Natural-Gas Production in Europe, Türkiye
• Trillion Energy International Inc. (CSE: TCF) (OTCQB: TRLEF) Works to Meet Increased Energy Demand in Europe, Türkiye
• InvestorNewsBreaks - Trillion Energy International Inc. (CSE: TCF) (OTCQB: TRLEF) (Frankfurt: Z62) CEO Featured in Latest Episode of the MiningNewsWire Podcast

Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF)

The QualityStocks Daily Newsletter would like to spotlightFathom Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF).

Environmental, social and governance (ESG) data is important because it helps measure the sustainability, long-term viability and ethical standards of companies. In the last couple of years, we have seen the reporting of issues linked to sustainability increase in shareholder reports, bolstered by regulatory mandates and/or voluntary disclosure. Data from 2022 shows that 98% of S&P 500 firms reported ESG data. Of these firms, 70% of them acquired some assurance on their ESG metrics. This is an increase from the 65% recorded in 2021. While ESG scores are useful in assessing companies, organizations may benefit from using them alongside other analytical techniques. Each company, such as Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF), has the task of deciding exactly what utility they wish to obtain from ESG scores and then tailor their software to accord greater emphasis on those parameters.

Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) is a publicly traded Canadian minerals exploration company focused on exploring high-grade copper and gold deposits in North America. The company owns the Storm Copper Project and the Seal Zinc Deposit in Nunavut, Canada, and is currently exploring the Buckingham Gold Vein and critical metals prospects in central Virginia. Aston Bay is also in the advanced stages of negotiation on other properties with high-grade critical minerals potential in these areas.

The company believes in responsible exploration and carries out its work programs to the highest standards of social responsibility, environmental stewardship and health and safety. Aston Bay cares about leaving a net positive impact on the communities in which it works and engages with local representatives, Indigenous groups and government agencies to build respectful relationships through dialogue and collaborative processes. Depending on the stage of exploration, these efforts may include employment, contracting, training, community benefits and other agreements.

Aston Bay conducts exploration through safe, socially and environmentally responsible and sustainable work practices. The company embeds core values of health and safety throughout its operations by adhering to strict health and safety standards and practices that meet and/or exceed industry standards and government codes and regulations.

The company is headquartered in Toronto.

Projects

Storm Copper

The high-grade Storm Copper Deposit is located 112 kilometers south of the community of Resolute Bay, Nunavut, on western Somerset Island, just south of the past-producing Polaris Pb-Zn Mine. The property comprises 173 contiguous mining claims, including the Storm Copper and Seal Zinc projects, covering an area of approximately 541,795 acres.

The property has good access to established shipping lanes, and the landscape provides favorable conditions for development of roads and a protected deep-water port. Exploration is supported through excellent infrastructure in the nearby hamlet of Resolute Bay.

Aston Bay is partnered with American West Metals (ASX: AW1) at Storm. American West is responsible for all exploration expenditures, having aggressively advanced the project toward production and earned an 80% interest. This affords excellent optionality to the company’s shareholders, as Aston Bay is free carried with no required expenditures until the completion of a bankable feasibility study.

American West recently completed an Australian JORC-compliant Maiden Resource Estimate for Storm; the North American 43-101 compliant resource estimate is expected in Q1 2024. American West is cashed up and plans a multimillion-dollar resource expansion and new discovery drilling program for the summer of 2024.

The Buckingham County Gold Project

The gold-bearing system at the Buckingham County Gold Project in Virginia lies within a belt hosting past producing mines, current gold mines and advanced gold explorations, stretching through Georgia, the Carolinas, Virginia, Nova Scotia and Newfoundland.

Buckingham hosts a “Kirkland Lake-style” high grade gold vein returning values consistently over one ounce gold per ton and is underexplored both at depth and along almost one mile of strike length. These types of veins have excellent ESG qualities, as they are typically mined using a small footprint underground method, with gold extracted using simple and environmentally friendly gravity methods.

Market Opportunity

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, is worth nearly $5 trillion. The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth.

This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council.

A report from Acumen Research and Consulting, a global provider of market intelligence and consulting services, valued the global copper market at $304.1 billion in 2022 and forecast that it will reach a market size of $496.8 billion by 2032, growing at a CAGR of 5.1% over the forecast period.

The report identifies a growing demand for copper in the electronics industry, as well as an expanding copper supply due to increasing production from existing mines and the rising number of mine development projects in developing nations, as driving factors in the rising value of the copper market.

Management Team

Thomas Ullrich is CEO and Director of Aston Bay. He has over 30 years of experience in mineral exploration and geoscience. Before joining Aston Bay, he was Chief Geologist North America for Antofagasta Minerals plc, investigating copper potential through extensive property evaluations and management of drill programs in the United States, Mexico and Canada. Prior to that, he was Senior Geologist for Almaden Minerals.

Sofia Harquail handles Investor Relations and Corporate Development at Aston Bay. She has over 15 years of experience in the private and public sectors of the mining industry. Before joining Aston Bay, she worked as a consultant for the Prospectors and Developers Association of Canada and for exempt market dealer Red Cloud Financial Services Inc. Ms. Harquail holds an M.A. from the University of Uppsala in Sweden and received her CPIR designation from the CIRI/Ivey Investor Relations Program. She also sits on the board of the Young Mining Professionals Toronto and is CSC Certified.

Aston Bay has a talented Board of Directors bringing broad experience from across the industry, encompassing resource expansion, mine development, mergers and acquisitions, and mining finance.

Ms. Jessie Liu-Ernsting has over 15 years of experience in the mining industry, spanning capital projects engineering, debt capital markets, private equity and corporate strategy at several firms, including Hudbay Minerals and Resource Capital Funds. She is currently VP Investor Relations and Communications at G Mining Ventures Corp.

Mr. Jeffrey R. Wilson has over 25 years’ experience in the mining industry, having served as a director, officer and advisor of multiple public and private companies in the mineral exploration and mining investment industries. Mr. Wilson is currently President & CEO of Precipitate Gold Corp.

Mr. Gary O’Connor has over 40 years of diverse experience as a mineral exploration and development professional in the management of successful resource projects as well as the evaluation, technical due diligence, and supervision of large mineral exploration and development projects through-out the world. While with Freeport, Mr. O’Connor worked on the due diligence and discovery of a major gold fraud on the Busang gold “deposit” in Kalimantan by Bre-X.

Mr. Mark J. Pryor is a geologist with a 40-year track record of successfully advancing multiple precious metal, copper, coal, REE and Li projects from discovery through to exploitation. He is currently Executive Vice President of the Exploration Division at The Electrum Group.

Aston Bay Holdings Ltd. (OTCQB: ATBHF), closed Monday's trading session at $0.085, off by 4.2793%, on 24,000 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0364/$0.1164.

Recent News

• Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) - Decoding What ESG Scores Can, Cannot Do
• InvestorNewsBreaks - Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF), American West Metals Hit Long Intervals of High-Grade Copper in Latest Batch of Drill Holes at Storm Project
• BHP Cautions That Copper Shortage Could Worsen as AI Booms

Emperor Metals Inc. (CSE: AUOZ) (FRA:9NH) (OTCQB: EMAUF)

The QualityStocks Daily Newsletter would like to spotlight Emperor Metals Inc. (CSE: AUOZ) (FRA:9NH) (OTCQB: EMAUF).

Earlier this week, gold saw its price surpass the $2,600 mark, a new high for the precious metal. Since the start of the year, gold has performed better than the expectations of many, starting in March when its price rose to $2,160 an ounce. This latest increase in price positions the precious metal as an attractive option for those looking to get fast returns. Given that the metal's price is already at a new high, some may wonder if it is it too late to jump on the bandwagon. Many experts believe it isn't, with some advising that investors add it to their investment portfolios. Below, we look at other reasons why investors may want to consider gold. The use of this precious metal in the electronics industry as well as in emerging technologies in the medical and renewable energy fields is giving rise to new demand for gold. As these applications increase, they could drive prices of gold higher, meaning that investors in the market are well positioned to benefit from this growing market. It should be noted, however, that while the precious metal's positive performance is alluring, the market can be unpredictable. Savvy investors may also want to study ways in which gold-explorer stocks, such as those of Emperor Metals Inc. (CSE: AUOZ) (OTCQB: EMAUF) (FRA: 9NH), and gold-extraction companies can help to add exposure to gold in their portfolios.

Emperor Metals Inc. (CSE: AUOZ) (FRA:9NH) (OTCQB: EMAUF) is an advanced stage gold exploration company focused on proving and developing the substantial resource potential of its flagship Duquesne West Gold Project located in the Tier 1 district of the Southern Abitibi Greenstone belt of Rouyn-Noranda, Quebec. The Project has a 2011 historical mineral resource estimate of 727,000 ounces of Au at 5.42 g/t and an average thickness of 5.71 m*.

In 2023, with the use of AI (Artificial Intelligence), Emperor Metals created the first ever 3D mineralized and geological model, which illuminated the potential to add significant ounces to this deposit. Using these models, Emperor’s had a very successful 2023 drilling campaign of 8,579 m. In addition to laterally extending high grade zones by intercepting grades of 15.8 g/t Au over 10.8 meters, Emperor encountered intercepts of lower grade bulk tonnage in the host rocks (1.69 g/t Au over 25 m). This led to envisioning a different strategy of exploration and the revelation that a conceptual open-pit potentially overlies this high-grade gold deposit. Historic core sampling began (2,500 m) for discovering overlooked lower grade gold in the host rock around the high-grade lenses. Lower grade bulk tonnage gold improves the open-pit economics by reducing stripping ratios and adding overlooked incremental ounces for open pit mining.

Emperor Metals is set to begin a fully funded Phase II 8,000 m drilling program in May 2024. The company also plans on assaying an additional 8,000 m of historic core within the open pit model. Emperor is working toward producing an updated NI 43-101 Mineral Resource Estimate by Q1 2025.

The company is led by a dynamic group of resource sector professionals who have a strong record of success in evaluating and advancing mining projects from exploration through to production, attracting capital and overcoming adversity to deliver exceptional shareholder value.

Project

Emperor Metals has an option to earn 100% ownership of the Duquesne West Gold Project, a mineral claim package comprising 38 claims covering approximately 1,389 ha (3,432 acres) in Quebec.

The Duquesne West Gold Property is located 32 kilometers northwest of the city of Rouyn-Noranda and 10 kilometers east of the town of Duparquet. The property lies within the historic Duparquet gold mining camp in the southern portion of the Abitibi Greenstone Belt in the Superior Province.

Emperor is targeting the potential multimillion-ounce resource in a combination of conceptual open pit and underground mining scenarios. A Phase I drill campaign and historical core sampling program was completed in 2023, which included resource confirmation and exploration drilling, focusing on delineating and growing the resource toward development.

The property hosts a historical inferred mineral resource estimate of 727,000 ounces of gold at a grade of 5.42 grams per ton (g/t) and average stope thickness of 5.71 m. The mineral resource estimate predates modern Canadian Institute of Mining guidelines, and a Qualified Person on behalf of Emperor Metals has not reviewed or verified the mineral resource estimate. Therefore, it is considered historical in nature and is reported solely to provide an indication of the magnitude of mineralization that could be present on the property. The gold system remains open for resource identification and expansion.

Reinterpretation of the existing geological model was created using artificial intelligence and machine learning. This AI model shows the opportunity for additional discovery of ounces by revealing gold trends unknown to previous workers and the potential to expand the resource along significant gold-endowed structural zones. Multiple scenarios exist to expand additional resources, which include:

• Underground High-Grade Gold
• Open Pit Bulk Tonnage Gold
• Underground Bulk Tonnage Gold

The Duquesne West-Ottoman property straddles the Porcupine-Destor gold localizing fault several kilometers east of the town of Duparquet. A number of previous drill campaigns have outlined an inferred resource of 4.17 million tons grading 5.42 g/t of gold (cut) or 6.36 g/t (uncut), as reported in the NI 43-101 report titled “Technical Report and Mineral Resource Estimate Update for the Duquesne-Ottoman Property, Quebec, Canada.”

Emperor Metals is funded for an 8,000-meter drilling program focusing primarily on adding ounces to the current resource within and lateral to the open pit model. An additional 8,000 m of historical core sampling and assaying is included in the budget to help build incremental ounces in the open-pit environment.

Market Opportunity

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, to be worth nearly $5 trillion.

The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth. This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council.

In May 2024, the market price of gold was approximately $2,340 per ounce.

Management Team

John Florek, P.Geol., is President, CEO and Director of Emperor Metals. He has more than 35 years of technical and senior management experience with major and junior mining companies, including roles as founder, vice president and director. He has helped identify and develop significant asset value for mines and exploration projects from grass roots through development. He has worked for several major mineral producers, including BHP, Placer Dome, Barrick, Teck and Detour Gold/Kirkland Lake Gold/Agnico Eagle.

Sean Mager is CFO and Director of Emperor Metals. He has worked more than 30 years in the mining sector, including extensive experience in corporate development, stakeholder relations, regulatory, financial and operations.

Alex Horsley is Head of Corporate Development and Director of Emperor Metals. He has more than 20 years of experience in the mining sector and capital markets with a focus on finance, marketing, management, corporate development and communications. He is founder and former CEO of Emperor Metals. He has assisted in raising more than C$40 million for exploration and development mining companies.

*Power-Fardy and Breede, 2011. The Mineral Resource Estimate (MRE) constructed in 2011 is considered historical in nature as it was constructed prior to the most recent Canadian Institute of Mining and Metallurgy (CIM) standards (2014) and guidelines (2019) for mineral resources. In addition, the economic factors used to demonstrate reasonable prospects of eventual economic extraction for the MRE have changed since 2011. A qualified person has not done sufficient work to consider the MRE as current. Emperor is not treating the historical MRE as current. The reader is cautioned not to treat it, or any part of it, as a current MRE.

Emperor Metals Inc. (OTCQB: EMAUF), closed Monday's trading session at $0.064055, off by 1.4538%, on 7,100 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.05715/$0.14505.

Recent News

• Emperor Metals Inc. (CSE: AUOZ) (FRA:9NH) (OTCQB: EMAUF) - Emperor Metals Inc. (CSE: AUOZ) (OTCQB: EMAUF) (FSE: 9NH) Details Recent Milestones, Upcoming Goals in MiningNewsWire Podcast
• Emperor Metals Inc. (OTCQB: EMAUF) (CSE: AUOZ) (FRA: 9NH) Seen as Standing Out in an Already Promising Sector
• What Current Gold Price Surge Says About Global Stability

Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF)

The QualityStocks Daily Newsletter would like to spotlight Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF).

The International Energy Agency (IEA) has revealed that transforming the world's energy industry to meet COP28 targets is "feasible." Climate change represents one of the most critical issues humanity has ever faced, and the 2023 United Nations Climate Change Conference set ambitious green-energy targets to put the globe on track to achieving carbon neutrality. According to the IEA, achieving the green-energy goals established at COP28 is feasible due to robust policies, significant manufacturing potential and "favorable economics." A recent IEA report says the world can double efficiency and triple green-energy capacity by 2030 but notes that this will require significant investment in stationary power-storage capacity as well as expedited grid connections. The COP28 targets should serve as the foundation for national climate targets, he noted, but countries will need to cooperate to ensure electrification occurs swiftly, there is enough power storage, and they can deploy fit-for-purpose grids for a speedy and secure transition. Adopting a country-specific approach to achieving the COP28 targets of tripling green-energy capacity by 2030 would also lower energy costs by 10% and cut emissions by 6.5 million tons. Adequate supplies of green-energy metals will be crucial to meeting these lofty energy-transition goals. A number of enterprises, such as Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF), are taking on this challenge in a bid to diversify the sources of these critical metals outside of China, which currently dominates the field.

Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF) is a strategic minerals company focused on locating and developing economic properties in the strategic metals and advanced materials space. The company aims to improve domestic specialty mineral infrastructure efficiencies to meet surging national demand from North American manufacturers, effectively positioning itself as one of the only North American suppliers of high purity natural graphite for hi-tech applications.

Reflex Advanced Materials is based in Vancouver, British Columbia. Its project portfolio includes the Ruby Graphite Deposit in Montana and the ZigZag Lithium Property in Ontario.

Projects

Ruby Graphite Project

Located in a mining-friendly jurisdiction in southwest Montana, the Ruby Graphite Deposit is a low cost, rapid re-entry opportunity that produced roughly 2,400 tons of graphite from 1902 to 1948. Reflex Advanced Materials holds mining rights for 755 hectares at the Ruby Graphite Project, with 96 federal lode mining claims. Recent samples assay at 95.8% to 98.4% total carbon.

The site is notable as the only combined U.S. graphite flake and vein graphite source. Vein graphite is ideal for energy storage applications, because it requires fewer steps to achieve purity than synthetic alternatives and is therefore far less environmentally damaging. This is expected to play a key role in the project’s development as demand for electric vehicles continues to surge.

In March 2023, the company announced its submittal of permit applications to the Bureau of Land Management in respect of its exploration of the Ruby Graphite Project. Its initial drill program, expected to take place in the summer of 2023, includes plans for 3,500 total meters of drilling, cored to an average depth of 130 meters. The targets for this drill program have been identified using historical data from original mine operations and data gathered for the initial 43-101 technical report on the project, dated January 31, 2023.

ZigZag Lithium Property

Located in the Thunder Bay Mining Division of Ontario, the ZigZag Lithium Property consists of eight mining claims spanning roughly 2,710 hectares. Mineralization at the property, most notably lithium, is based in pegmatite dikes and concentrated in spodumene crystals, which are consistent throughout the entire unit.

Spodumene is readily observable in outcrops and in drill cores, with crystal sizes ranging from 3-15cm, on average.

Reflex Advanced Materials and American Energy Technologies Company Metallurgical Partnership

Reflex Advanced Materials has entered into a material processing agreement with American Energy Technologies Co., which is based in Arlington Heights, Illinois, to conduct metallurgical testwork with the goal of creating a technical support data package for Reflex’s target customer base, U.S. Federal agencies and qualification programs with hi-tech customers in the battery and battery storage business.

The resulting coated, spherionized, purified graphite (CSPG) material that is expected to be created from the aforementioned tests will be used to provide potential customers of CSPG with samples so that they can begin the material qualification process.

Market Opportunity

Graphite is an ideal battery anode and has dominated the market since the proliferation of lithium-ion batteries. Despite this demand, there is currently no significant production of lithium-ion battery anode material in North America.

Instead, most graphite sold in North America today is sourced from Chinese producers. U.S. President Joe Biden highlighted this sourcing disparity in a 2022 address:

“The United Stated depends on unreliable foreign sources for many of the strategic and critical materials necessary for the clean energy transition – such as lithium, nickel, cobalt, graphite and manganese for large-capacity batteries,” he said. “Demand for such materials is projected to increase exponentially as the world transitions to a clean energy economy.”

The U.S. Department of Energy is in the process of awarding $2.8 billion to expand domestic manufacturing of batteries for electric vehicles and combat this foreign dependency. Reflex Advanced Materials has identified its Ruby Graphite Project as a prime candidate for U.S.-sponsored initiatives due to the rarity and scarcity of natural graphite deposits in the country.

Processing graphite domestically in the U.S. is expected to provide Reflex Advanced Materials a competitive advantage as manufacturers begin to seek out American supply in the face of increased diplomatic tension. This is critical, as a rise in anode demand is expected to fuel a shortage of 8 million tonnes of graphite by 2040. World Bank Group projects 494% growth in total graphite demand by 2050.

Leadership Team

Paul Gorman is the CEO and a Director of Reflex Advanced Materials. He brings to the company over 25 years of experience in junior mining finance, public listings, viability assessment and operational rationalization. For 18 years, Mr. Gorman served as president and managing partner of Riverbank Capital, where he played an instrumental role in raising more than $85 million for small-cap companies. In 2008, he funded Industrial Minerals Inc. (later Northern Graphite) and served in an advisory role for four other graphite companies, contributing significantly to the revitalization of the junior graphite space in North America. Mr. Gorman founded Mega Graphite Inc. in 2009 and has served as chief executive for three other companies.

Tasheel Jeerh, CPA, is the company’s CFO. He is a finance and accounting professional with over a decade of experience spanning both public and private sectors. Prior to joining Reflex Advanced Materials, Mr. Jeerh played a pivotal role in the growth of a private upstream oil and gas firm, dealing with over $2 billion in M&A activity and $1 billion in financing activities. He gained his designation at PricewaterhouseCoopers, where he worked as a manager in the assurance practice.

Greg Bell is Project Manager for Reflex Advanced Materials. He is a multi-disciplined engineering management professional with more than 40 years of experience in the natural resources sector. Mr. Bell has successfully built and managed several start-up operations in various capacities. He has been active in graphite and lithium exploration for the past seven years.

Christopher W. Hill leads the company’s Corporate Development initiatives. He is an investor and entrepreneur with over a decade of experience in the capital markets. Mr. Hill began his career as an investment advisor and then began to consult and advise private companies on their paths to becoming publicly traded. He specializes in corporate development and strategic financing utilizing his large network in the capital markets.

Reflex Advanced Materials Corp. (RFLXF), closed Monday's trading session at $0.0282, off by 37.3333%, on 750 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0203/$0.2269.

Recent News

• Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF) - The Market for ESG Reporting Software Poised for Explosive Growth
• Dutch Stadium Makes History by Using Only Green Energy During Soccer Game
• Russia Moves to Exploit Bolivia's Lithium Reserves

HealthLynked Corp. (OTCQB: HLYK)

The QualityStocks Daily Newsletter would like to spotlightFathom HealthLynked Corp. (OTCQB: HLYK) .

HealthLynked Corp. (OTCQB: HLYK) is at the forefront of a transformative movement in healthcare, utilizing its extensive collection of health data to improve care for all. With a commitment to leveraging its advanced technology platforms, HealthLynked employs a sophisticated, cloud-based network that serves as a comprehensive repository for personal health data. This system not only simplifies the management and archiving of medical records but also enables the application of AI to deliver personalized healthcare insights. Through deep analysis of this data, HealthLynked’s AI capabilities help identify the root causes of diseases, tailor healthcare solutions to individual needs, and accelerate medical discoveries.

In addition to these capabilities, HealthLynked provides a user-friendly platform for booking healthcare appointments, similar to how OpenTable operates for restaurant reservations. This feature allows patients to conveniently book appointments with healthcare providers across the country, including options for telemedicine consultations, enhancing accessibility and efficiency in healthcare service delivery.

Strategically headquartered in Naples, Florida, HealthLynked operates through three primary divisions: Health Services, Digital Healthcare, and Medical Distribution. Each division supports the company’s mission to revolutionize patient care and health management. Positioned as a potential leader in healthcare AI, HealthLynked is dedicated to shaping the future of the industry over the next 20 years, driving significant advancements in healthcare accessibility and effectiveness through innovation and technology.

Strategic Initiatives and Operational Highlights

The company’s commitment to enhancing global health is evident in its dual goals: transforming healthcare through advanced technology and creating a patient-centric network that accelerates medical discoveries and the development of disease cures.

HealthLynked’s intellectual property portfolio is robust and strategically developed to enhance healthcare delivery and management. In March 2023, HealthLynked was granted a patent for a groundbreaking healthcare-specific wireless access point, known as the “Patient Access Hub.” This technology significantly improves the efficiency of healthcare practices by enabling real-time monitoring of patient flow within facilities. It intelligently determines patients waiting in exam rooms and calculates wait times, alongside other critical practice metrics. This system not only enhances patient experience by reducing unnecessary wait times but also optimizes resource allocation within healthcare settings.

Additionally, in October 2023, HealthLynked filed a patent application for its advanced AI program, ARI (Augmented Real-time Interface). ARI acts as a virtual doctor for patients, capable of performing medical intake, booking appointments, and providing personalized medical recommendations based on a patient’s medical history. By integrating these tasks, ARI streamlines the healthcare process, reducing the administrative burden on healthcare providers and ensuring that patients receive timely and tailored healthcare advice. This AI-driven interface enhances the accessibility and personalization of healthcare, embodying HealthLynked’s commitment to leveraging technology for better health outcomes. The company recently launched HealthLynked 3.2.0, an advanced version of its application, incorporating telemedicine, AI-driven personal healthcare guidance, and remote patient monitoring – setting a new standard in healthcare technology.

Market Position and Future Outlook

According to Facts and Figures Research, a research and consulting firm, the global market for patient-centric healthcare applications is projected to reach $41.6 billion by 2030, growing at a CAGR of 18.77% from 2022. HealthLynked’s offerings align perfectly with this expansive market opportunity, especially with increasing demands for digital health solutions and data management in healthcare.

HealthLynked’s strategic direction, spearheaded by its seasoned management team, is designed to leverage these market dynamics, enhancing patient engagement and healthcare efficiency on a global scale.

Management Team

Michael T. Dent, M.D., Founder, CEO, and Chairman, brings extensive experience from his foundational role at NeoGenomics and leadership in various healthcare and technology sector companies.

David Rosal, CFO, with previous senior roles at Teradata and McDonald’s Corporation, brings a wealth of expertise in financial and business integration strategies essential for growth and operational efficiency.

Chris Hall, CTO, with a strong background in global technology development from his time at Siemens and several patents to his name, is instrumental in driving the innovation and technological advancement at HealthLynked.

Bill Crupi, Operations Manager, has a proven track record in streamlining operations and enhancing productivity across multiple sectors within the healthcare industry. His expertise is crucial in maintaining the operational excellence that HealthLynked is known for.

Michael Paisan, Director of Investor Relations, leverages his extensive experience in finance and communications to enhance HealthLynked’s relationships with investors and stakeholders, ensuring transparent and effective communication of the company’s value and growth strategy.

Gagan Babber, Manager of Software Development, oversees the HealthLynked development teams based in the U.S. and India. With a robust background in engineering and software development, he plays a critical role in guiding the technological direction of HealthLynked’s products. His expertise in developing scalable, innovative software solutions is essential for driving the company’s technical initiatives forward and ensuring that HealthLynked stays at the forefront of digital healthcare technology.

HealthLynked Corp. (OTCQB: HLYK), closed Monday's trading session at $0.04295, up 3.494%, on 6,592 volume. The average volume for the last 3 months is 72,593 and the stock's 52-week low/high is $0.033/$0.0999.

Recent News

• HealthLynked Corp. (OTCQB: HLYK) - InvestorNewsBreaks - HealthLynked Corp. (HLYK) Announces Expansion of Its Telehealth Services Nationwide, New Service
• Detailed Data Could Save Customers Billions in FSA Funds for Healthcare
• How Health Technology Could Improve Customer Experience

GivBux Inc. (OTC: GBUX)

The QualityStocks Daily Newsletter would like to spotlightFathom GivBux Inc. (OTC: GBUX) .

GivBux Inc. (OTC: GBUX) is a publicly traded super app and charitable giving platform. The company is creating a sharing economic community of brands and consumers in which consumers have an easier and more convenient way to shop and buy, merchants have a more efficient and profitable way to advertise, and charities receive built-in contributions from the community’s transactions.

The GivBux Super App revolutionizes shopping by offering a user-friendly tool to make purchases swiftly at over 100 national retailers, along with an expanding roster of local merchants. Users earn cash back on every purchase, a portion of which can be directed toward a charity of their choice, embodying GivBux’s commitment to giving back. Additionally, the app is evolving to include numerous functionalities like social networking, e-commerce, banking, messaging, food delivery and transportation, following the super app model.

GivBux is forging a new path in charitable giving, with aspirations to build the largest community of givers in the United States, and eventually globally. The company believes it is uniquely positioned to make a major contribution to society by overlapping the worlds of commerce and philanthropy.

The GivBux Super App is currently available for free on the Google Play Store and the Apple App Store.

The company is headquartered in Newport Beach, California.

Products

The company, through wholly owned subsidiary GivBux Global Partners Inc., is engaged in the fintech mobile wallet sector, specifically as a point-of-sale payment system by means of a consumer mobile wallet. GivBux uses smartphone technology to bridge consumers and merchants together without the need for traditional plastic cards or paper cash.

The GivBux mobile app has been designed to store, send and receive funds; donate; and make real-time purchases at top retail brands, restaurants and other venues. The brands benefit, because they are empowered with a data-rich marketing tool to reach and retain consumers through their mobile phones.

With GivBux, recipients can use funds instantly by paying with their mobile phones at thousands of locations. GivBux rewards all users for using the app every time they make a purchase and every time their friends, friends of friends and stranger friends make purchases with the GivBux mobile wallet. These rewards can be redeemed for cash to pay at participating retail stores, restaurants, cinemas, entertainment venues and more.

Moreover, GivBux allows users to contribute to a charity or worthy cause of their choice. To encourage giving and recommendations, a trending ‘Top 10 List’ of all charities will be generated and displayed on the mobile wallet based on ongoing contributions by GivBux users.

Market Opportunity

A report from Future Market Insights, a New York-based market research organization, estimated the worldwide mobile wallet market at $9.5 billion in 2023. The report projects that in 2024 the industry is likely to reach a valuation of $11.9 billion, and, by 2034, the mobile wallet market is forecast to grow to a value of $138.5 billion, achieving a CAGR of 27.8% over the forecast period.

Key market growth drivers include payment convenience, transaction security and continuing technological innovation. The report points out that mobile wallet payments are widely accepted worldwide, fueled by a rise in digital transactions and a growing use of mobile phones for simple and effective payment options. Innovations like blockchain integration, contactless payments and artificial intelligence are improving functionality and user experience while staying ahead of rapidly evolving digital payment trends, according to the report.

Management Team

Umesh Singh is President and Director at GivBux. He is a Certified Professional Accountant (Canada) with more than 25 years of experience in accounting and finance. He began his career at PwC before joining Hayes Stuart Little & Company (now Grant Thornton), where he was Senior Accountant-Manager and later Partner. Prior to being named GivBux president, he was a member of the GivBux Advisory Board for more than three years.

Michael Arnkvarn is Vice President of International Business Development at GivBux. He has over 30 years of experience in management, sales and marketing. He managed several medium and large agribusiness and environmental businesses before founding Collagenna Skin Care Products, a natural health products and cosmetics company, in 2004. He has been CEO of multiple public small-cap companies and co-founder of a start-up cannabis company that eventually sold for more than $800 million.

GivBux Inc. (OTC: GBUX), closed Monday's trading session at $0.53, even for the day. The average volume for the last 3 months is 1,454 and the stock's 52-week low/high is $0.20005/$1.94.

Recent News

• GivBux Inc. (OTC: GBUX) - InvestorNewsBreaks - GivBux Inc. (GBUX) Marks Milestone in 'Evolution of Corporation' with Submission of Required Docs to SEC
• InvestorNewsBreaks - GivBux Inc. (GBUX) Moves to Qualify as OTCQB Corporation
• InvestorNewsBreaks - GivBux Inc. (GBUX) Releases Outline of Near-Term Goals, Objectives for Expansion and Super App Enhancements

Software Effective Solutions Corp. (OTC: SFWJ)

The QualityStocks Daily Newsletter would like to spotlight Software Effective Solutions Corp. (OTC: SFWJ).

Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) is a global infrastructure and holding company in the cannabis industry. MedCana currently has five companies focused on pharmaceutical cannabis production, as well a software company focused on managing processes for plant-to-patient operations. The recent acquisition of an irrigation and greenhouse technology company has rounded out MedCana’s portfolio of holdings.

MedCana’s focus is on developing clients and companies in Latin America, initially in Colombia, and partnerships with laboratories, research facilities and hospitals throughout the world. MedCana is building the technology, laboratories, growing facilities and scientific teams to provide premium pharmaceutical-grade cannabis extracts to the world.

MedCana’s goal is to be the world’s premier resource for pharmaceutical cannabis products. The company believes its advantage is its global view and reach. From initial cultivation to final product, MedCana aims to help partners produce pharmaceutical CBD and other extracts that will have no equal.

The company’s mission is to utilize its technology to partner with and develop companies that provide premium pharmaceutical-grade cannabis extracts with absolute integrity, sustainability and social responsibility. MedCana’s team of pharmaceutical scientists includes some of the most respected chemists in the world. They aim to ensure that the company’s customers and partners create premium cannabis extracts that meet the growing worldwide demand. MedCana’s software is designed to ensure traceability and quality from seed to finished product.

MedCana is headquartered in Austin, Texas, with offices in Colombia.

Production

MedCana announced in May 2023 the beginning of full-scale production of non-THC cannabis for export to Europe in response to high demand in that market. This expansion comes after the successful completion of full crop cycle testing and infrastructure development at production sites in Columbia.

The recent acquisition of the assets of Tokan Corp., a software company focused on creating an enterprise resource planning (ERP) platform for the cannabis industry, and Eko2O S.A.S., a greenhouse and irrigation engineering company, has positioned MedCana for explosive growth in the region.

As a MedCana subsidiary, Eko2O SA will increase the company’s revenue potential in Central and South America. The subsidiary specializes in the construction and distribution of greenhouses and sophisticated irrigation platforms. A positive outlook has resulted from the company’s expansion as it investigates new opportunities for greenhouse and irrigation system installations in Panama and Uruguay. These opportunities are expected to accelerate Eko2O’s development and strengthen its position as a top supplier of innovative agricultural solutions in cannabis and other sectors that are quickly moving to high technology agricultural production.

In addition, MedCana has started talks with the government in Argentina about possible incentives for beginning operations in that country as part of its ongoing worldwide development strategy. Support from the Argentinean government and the start of new operations there would greatly increase MedCana’s market share in Latin America and solidify the company’s position as the market leader in the cannabis industry.

Market Opportunity

According to a report by Grand View Research, a San Francisco-based market research and consulting company, the global cannabis extract market was valued at $3.5 billion in 2022 and is expected to expand at a CAGR of 20% from 2023 to 2030 to be worth more than $15 billion.

Growing demand for cannabis extracts, including oils and tinctures, and the increased legalization of marijuana for the treatment of different chronic ailments like arthritis, Alzheimer’s, anxiety and cancer are driving the expansion of the industry. The marijuana derivative industry is flourishing due to a greater understanding of its various medical benefits.

Management Team

Jose Gabriel Diaz is CEO of MedCana. He has successfully built, grown and sold multiple telecom companies. He was senior vice president of sales at IP Communications, a national high-speed data provider. He also founded Reallinx, a national data carrier later sold to GTT Communications. Additionally, he is currently president of the A.E.M. Business and Entrepreneurship Association in Austin, Texas.

Claudio Jiménez Cartagena, QF, Ph.D. is Chief Scientific Officer at MedCana. He joined MedCana after working with Sosteli Pharma as Technical Director and serving as a director consultant for the Corporation for Agricultural Industrial Development at the University of Antioquia in Colombia. Before that, he worked as the scientific director at the Institute of Food Science & Technology. He holds a bachelor’s degree in pharmaceutical chemistry, a master’s degree in basic biomedical sciences and a doctoral degree in Environmental Engineering from the University of Antioquia.

Julián Alberto Londoño Londoño, Ph.D., is Senior Vice President of Operations at MedCana. He previously served as general manager for the Corporation for Agricultural Industrial Development, and as Chief Scientific Officer at Sosteli Pharma in the Resource Management Department. He has developed multiple U.S. patents, and recently served as senior advisor to the Secretariat of Agriculture Development for the Government of Antioquia. He holds a doctorate in Chemical Sciences from the University of Antioquia.

Software Effective Solutions Corp. (OTC: SFWJ), closed Monday's trading session at $0.038, up 8.5714%, on 46,333 volume. The average volume for the last 3 months is 19,042 and the stock's 52-week low/high is $0.000001/$0.09.

Recent News

• Software Effective Solutions Corp. (OTC: SFWJ) - Research Suggests CBD Can Kill Mosquito Larvae
• Missouri Authorities Raid Shops Searching for Hemp Edibles Containing Intoxicants
• California Governor Announces Emergency Regulations Banning THC-Infused Hemp Products